Sign In
16 Aug 2018 14:00
16 August 2018
Cello Health plc
Total Voting Rights
In conformity with the FCA's Disclosure Guidance and Transparency Rules, Cello Health plc ("Cello" or the "Company") confirms the following:
As at 16 August 2018, Cello's issued share capital consists of 105,164,241 ordinary shares of 10 pence each ("Ordinary Shares"). The Company holds 453,000 Ordinary Shares in treasury. The total number of current voting rights in the Company is therefore 104,711,241 Ordinary Shares.
The above figure (104,711,241 Ordinary Shares) may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
Cello Health plc | 020 7812 8460 |
| |
Mark Scott, Chief Executive |
|
| |
Mark Bentley, Finance Director |
|
| |
|
|
| |
Cenkos Securities (Nomad) | 0207 397 8900 |
| |
Mark Connelly / Harry Hargreaves
|
|
| |
Buchanan Communications | 0207 466 5000 |
| |
Mark Court Jamie Hooper Sophie Wills |
|
| |
About Cello Health plc
Cello Health plc is a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. Cello Health plc currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.
Cello Health plc enables clients to commercialise and differentiate their assets and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilising latest thinking, technology and digital solutions.
Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York City, Philadelphia PA, London, Edinburgh, Farnham and Cheltenham.
For further information, please visit: https://cellohealthplc.com
Follow the stocks
